New products and services from Ethicon, MeridianEMR, the American Society for Radiation Oncology, and ALOKA Co., Ltd.
For more information, including risks, visit http://www.ethicon360.com/.
New iPhone application assists with patient data, billing
For more information, visit http://www.meridianEMR.com/.
Group offers list of radiation safety questions for patients
Fairfax, VA-The American Society for Radiation Oncology (ASTRO) has published a list of radiation safety questions for cancer patients and their caregivers to ask their physician about the quality assurance protocols of their radiation therapy treatments. By asking the right questions, patients can understand how these treatments work to eliminate their cancer and learn about safety checks and balances that go into treatment, according to ASTRO. Patients can view the questions at http://www.rtanswers.org/treatmentinformation/questions/safetyquestions.aspx.
For more information, visit http://www.rtanswers.org/.
Compact ultrasound system offers several imaging modes
Wallingford, CT-ALOKA Co., Ltd., has launched the ProSound Alpha 6, a full-featured, compact ultrasound system. The system's high-power processor allows a number of different imaging modes previously seen only in high-end systems, according to the company.
The ProSound Alpha 6 is available with or without 3-D/4-D imaging and is released with a suite of application-specific probes and software, customizable reports, and network/EMR connectivity capabilities.
For more information, visit http://www.aloka.com/.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.